Related Experiment Video

Updated: Jun 13, 2025

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

7.2K

NEJM at ESMO - Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer

Eric J Rubin, Oladapo O Yeku, Stephen Morrissey

    The New England Journal of Medicine
    |September 16, 2024
    PubMed
    Abstract

    No abstract available in PubMed .

    More Related Videos

    Modeling Brain Metastasis by Internal Carotid Artery Injection of Cancer Cells
    10:01

    Modeling Brain Metastasis by Internal Carotid Artery Injection of Cancer Cells

    Published on: August 2, 2022

    6.4K
    High-Content Screening Assay for the Identification of Antibody-Dependent Cellular Cytotoxicity Modifying Compounds
    13:59

    High-Content Screening Assay for the Identification of Antibody-Dependent Cellular Cytotoxicity Modifying Compounds

    Published on: August 18, 2023

    1.9K

    Related Experiment Videos

    Last Updated: Jun 13, 2025

    Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
    08:59

    Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

    Published on: December 11, 2017

    7.2K
    Modeling Brain Metastasis by Internal Carotid Artery Injection of Cancer Cells
    10:01

    Modeling Brain Metastasis by Internal Carotid Artery Injection of Cancer Cells

    Published on: August 2, 2022

    6.4K
    High-Content Screening Assay for the Identification of Antibody-Dependent Cellular Cytotoxicity Modifying Compounds
    13:59

    High-Content Screening Assay for the Identification of Antibody-Dependent Cellular Cytotoxicity Modifying Compounds

    Published on: August 18, 2023

    1.9K

    Related Concept Videos

    Targeted Cancer Therapies02:57

    Targeted Cancer Therapies

    7.5K
    The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
    There are several types of targeted therapies against...
    7.5K

    Articles linked to this work by shared authors, journal, and citation graph.

    IMMU-NO versus yes: Applicability of immune checkpoint inhibitors in gynecologic cancers.

    Cancer·2026

    Antibody-drug conjugates in gynaecological cancers: opportunities and challenges.

    Nature reviews. Clinical oncology·2026

    First-In-Human Trial of Encapsulated Cells Constitutively Expressing Localized IL2 in Patients with High-Grade Serous Ovarian Carcinoma.

    Clinical cancer research : an official journal of the American Association for Cancer Research·2026

    Normalizing the Tumor Microenvironment: A New Frontier in Ovarian Cancer Therapy.

    International journal of molecular sciences·2026

    Hypoxia induced VEGF secretion promotes resistance to bispecific T-cell engagers.

    Signal transduction and targeted therapy·2025

    Serial Circulating Tumor DNA Sequencing to Monitor Response and Define Acquired Resistance to Letrozole/Abemaciclib in Endometrial Cancer.

    JCO precision oncology·2025

    Continuous Glucose Monitoring in Non-Insulin-Treated Type 2 Diabetes.

    The New England journal of medicine·2026

    Adult Attention Deficit-Hyperactivity Disorder.

    The New England journal of medicine·2026

    Long-Acting HIV Therapy in African Adults with Adherence Challenges.

    The New England journal of medicine·2026

    Phase 2 Trial of Icotrokinra for Patients with Ulcerative Colitis.

    The New England journal of medicine·2026

    Study protocol of a prospective, non-interventional cohort study evaluating the benefits of transjugular intrahepatic portosystemic shunt in patients with hepatocellular carcinoma receiving first-line atezolizumab plus bevacizumab (NISTIPS TRITICC-4, IKF092).

    Future oncology (London, England)·2026

    Transarterial Computed Tomographic Angiography in Patients With Impaired Renal Function Undergoing Endovascular Aortic Repair.

    Vascular and endovascular surgery·2026

    8-Chloro-cyclic AMP mediates growth inhibition of breast cancer cells via regulation of Yin-Yang 1 and estrogen receptor α levels.

    BMB reports·2026

    Atorvastatin protects cardiomyocytes from doxorubicin toxicity by modulating YAP/TAZ signaling.

    BMB reports·2026

    Contrast-Associated Acute Kidney Injury in Oncology Patients During Active Chemotherapy: A Saudi Arabian Retrospective Study.

    Medical science monitor : international medical journal of experimental and clinical research·2026

    Dual-Targeting Nanomicelles Co-Loading Sorafenib and Artesunate Combats Hepatocellular Carcinoma via the Synergistically Enhanced Ferroptosis Strategy.

    Advanced healthcare materials·2026
    See all related articles
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies
    Jove
    Visualize
    Contact Us